Fri. May 24, 2024 1:30 PM - 2:30 PM Room 5 (G409)

Chair: Joseph Zohar (National Post-Trauma Center, Research Foundation by the Sheba Medical Center, Israel)

Symposium outline:
One of the biggest challenges facing clinicians and researchers is to be precise in the medications they use. Our current nomenclature, which is disease-based, uses the terms "antidepressants" and "antipsychotics" (including "second generation" antipsychotics) "mood stabilizers","anxiolytics" etc., which does not do justice to the wealth of neuroscience knowledge that has been accumulated in the past 60 years, since these terms were initially coined.
Prof. Zohar will open the symposia by introducing the growing interest in NbN in the scientific arena, as well as providing a practical demonstration of how to use the search engine of NbN. In the second talk, Prof. Blier will help us dive deeper into the potential of moving to pharmacologically driven concepts by illustrating how taking into consideration the dose of the medication has clear clinical implications in practice and research. In the third talk, Prof. Correll will talk about how using NbN can help to make updated, precise pharmacological steps in the treatment of psychosis. Finally, Dr. Seker will bring the early career voices on NbN from different perspectives, including the perception of the scientific basis for informed prescribing.
In this symposium, there will be ample time for Q&A, which will be led by Prof. Zohar.

Fri. May 24, 2024 1:30 PM - 2:30 PM Room 10 (G402)

Chair: Suresh Sundram (Monash University)

Summary:
Panel discussion session with representatives from three to four pharmaceutical manufacturers. This 60-minute session will consist of two parts: oral presentations by representatives of each company and a panel discussion. In the first half of the session, each representative will speak freely about their latest initiatives and future prospects for approximately 10 minutes (no Q&A). After the oral presentations by each company, a panel discussion will be held with representatives as panelists and a chairperson selected from CINP's EC members. The main points of the panel discussion will be presented in advance.

Fri. May 24, 2024 3:00 PM - 4:00 PM Room 1 (Hall C)

Chair: Christoph U. Correll (Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA), Tetsuro Kikuchi (Otsuka Pharmaceutical)

Fri. May 24, 2024 3:00 PM - 4:00 PM Room 10 (G402)

Chair: Po-See Chen (Department of Psychiatry, National Cheng Kung University Hospital, Tainan, Taiwan), Chau-Shoun Lee (Department of Medicine, MacKay Medical College)

Fri. May 24, 2024 3:00 PM - 4:00 PM Room 5 (G409)

Chair: Robert D. Buenaventura (Department of Psychiatry, University of the East Ramon Magsaysay Memorial Medical Center Inc., Quezon City, Philippines)

Abstract:
The global rise in the elderly population, particularly those with dementia, underscores the urgency of addressing the associated challenges. In the Philippines, dementia prevalence among older adults is higher than the regional average, emphasizing the need for effective screening tools. Undetected dementia rates vary globally, necessitating locally validated tools like MMSE-P and MoCA-P. Concurrently, raising awareness about dementia is crucial for early detection.
Further, the complex nature of behavioral and psychological symptoms of dementia (BPSD) requires exploration, considering gene interactions, gender-specific effects, and diverse environmental influences. A study on a Filipino population explored associations between APOE, DRD3, BDNF, and COMT polymorphisms and BPSD endophenotypes, revealing significant associations with APOE, DRD3, and COMT minor alleles. Ethnic variations in genetic risk for BPSD underscore the complex interplay of genetics and environment.
The evolving landscape of Alzheimer's Disease (AD) diagnosis and management involves biomarkers for precise detection, enhancing diagnostic accuracy crucial for emerging disease-modifying therapies. Symptomatic therapies persist, but the promise of slowing AD progression is evident with disease-modifying therapy. The multimodal approach to dementia prevention, considering risk factors and early detection, is paramount. An innovative component incorporated in this intervention is INDAK, which captures the unique culture of Filipinos.

Learning Objectives:
1. Recognize the increasing prevalence of dementia in the Philippines and identify locally validated screening tools available for early detection and timely diagnosis.
2. Analyze findings from a Philippine genetic study which explores the relationships between APOE, DRD3, BDNF, and COMT polymorphisms and BPSD endophenotypes
3. Explain the role of biomarkers and evaluate the significance of a culturally sensitive, multimodal approach in dementia prevention.

Keywords:
#dementia #BPSD #ethnopsychiatry #AlzheimersDisease #crosscultural

Fri. May 24, 2024 3:00 PM - 4:00 PM Room 4 (Hall D1)

Chair: Suresh Sundram (Monash University)

Sat. May 25, 2024 2:30 PM - 3:30 PM Room 2 (Hall B7 (1))

Chair: Gabriella Gobbi (McGill University)

Abstract:
With this mini symposium, the CINP Psychedelic Pharmacology Global Network (GNC) aims at giving an overview of the state of the art of preclinical and clinical research on the therapeutics of psychedelics. We will offer basic knowledge to scientists who want to know more about the mechanism of action of psychedelics and their clinical application.
Dr. Gobbi will introduce the session explaining the goal of the symposium and the role of the CINP Psychedelic Pharmacology GNC in the present and future.
Then, Dr. De Gregorio will give an overview on the historical classification of psychedelics and hallucinogenic compounds and the need for a more comprehensive modern classification.
Dr. Tani will focus on the description of clinical evidence of psychedelics. He will demonstrate the clinical and neuroimaging findings from their double-blind, randomized, placebo-controlled trial of intravenous ketamine infusion in patients with treatment-resistant depression (TRD). Then, the clinical evidence on the therapeutic benefits and adverse effects of psychedelics, especially the use of psilocybin for depression, will be reviewed. Furthermore, he will present their upcoming clinical trial of psilocybin in Japan in patients with TRD.
Dr. Musazzi will give an overview of mechanistic studies in preclinical models aimed at trying to elucidate the cellular mechanisms underlying the pharmacological properties of psychedelics. Indeed, preclinical studies have much to offer psychedelic research as they allow a tight control of experimental parameters and the possibility of elucidating the relevant signaling cascades that mediate therapeutic outcome. Nevertheless, the mechanisms involved in the effects of psychedelics are still far to be fully elucidated.
Finally, Dr. Gobbi and Dr. Martinotti will lead a round table discussion involving basic researchers and clinicians. The session will include a question-and-answer segment from the audience, focusing on the deepening of key features and concerns regarding the use of psychedelics as therapeutic drugs.
Overall, the mini symposium aims to provide fundamental information on the current status of psychedelics and to foster an open dialogue on psychedelic research between clinicians and preclinical scientists. This initiative seeks to promote the translational approach necessary for gaining further insights into the mechanisms of rapid psychotropic effects and for advancing psychedelics toward clinical practice.

Sat. May 25, 2024 2:30 PM - 3:30 PM Room 3 (Hall D7)

Chair: Joseph Zohar (National Post-Trauma Center, Research Foundation by the Sheba Medical Center, Israel), Lakshmi Yatham (University of British Columbia)

Rationale for World Guidelines – Lakshmi (15 + 5 Q&A min)
Presenting the World Bipolar Guidelines – Pierre Blier (15 + 5 Q&A min)
New Directions in Guidelines - Zohar (10 min)
Discussion and Summary - All (10 min)

Abstract:
Current guidelines in psychiatry often reflect national or continental perspectives, tailored to available services, cultural nuances, and infrastructural capacities. These guidelines typically adopt a hierarchical approach to intervention levels. In 2023, a landmark collaboration was forged between three major intercontinental psychiatric associations— The International College of Neuropsychopharmacology (CINP), The World Psychiatric Association (WPA), and World Federation of Societies of Biological Psychiatry (WFSBP)—to address these challenges.
This symposium aims to showcase the milestones of this unprecedented collaboration and present the current status of its flagship initiative. Dr. Lakshmi will elucidate the rationale for developing intercontinental guidelines, drawing from extensive experience in guideline development.
The focus will initially be on updating the existing CINP guideline on bipolar disorder and adapting it to a novel framework. Prof. Blier, a taskforce member, will provide insights into the ongoing development of the global bipolar disorder guideline.
Emphasizing the vision of inclusivity, the guideline aims to incorporate service availability, cultural considerations, and economic factors, rendering it sensitive to local contexts. For instance, adaptations will vary based on whether the guideline is intended for implementation in Africa or North America.
Another distinguishing feature of this guideline is its patient-focus approach. Departing from traditional decision trees, the guideline will prioritize understanding the patient's vignette. Leveraging artificial intelligence (AI) and search algorithms, tailored recommendations will be generated based on the patient's profile and the guideline's location of implementation.
The symposium will facilitate an extensive Q&A session, fostering an open dialogue to propel this pioneering initiative forward.

Sat. May 25, 2024 1:00 PM - 2:00 PM Room 5 (G409)

Chair: Joseph Zohar (National Post-Trauma Center, Research Foundation by the Sheba Medical Center, Israel)

Overview:
CINP has recently formed six Global Networking Communities (GNCs) to provide a collaborative and inclusive environment for those with shared subspecialist interest to network with global peers, develop and obtain funding for collective research projects, pursue educational goals, raise awareness of new treatment modalities and build symposia proposals for CINP World Congresses.
Membership of the GNCs is open to all CINP members in good standing, who are eligible to join a maximum of two communities. The first six GNCs to be formed cover the following subspecialist fields:
Difficult to Treat Depression, Digital Intervention, Fast Acting Medications/Psychedelics, Neuromodulation, OCD Spectrum, Precision Psychiatry.
In this session, four of the GNC leaders will introduce their communities and provide an overview of the activities they have planned for the next 12 months.
Audience members will have the opportunity to ask questions and to propose areas of activity for the various communities.

Sun. May 26, 2024 2:50 PM - 3:50 PM Room 4 (Hall D1)

Chair: Tianmei Si (Peking University Sixth Hospital & Peking University Institute of Mental Health), Hiroyuki Uchida (Department of Neuropsychiatry, Keio University School of Medicine)